SCHEMBL7701146

SCHEMBL7701146

Cc1cccc(C)c1OCC(C)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 10/20 0.66
LMNA P02545 5/20 0.66
CYP2D6 P10635 3/20 0.66
SCN1A P35498 2/20 0.66
SCN5A Q14524 2/20 0.66
SCN9A Q15858 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP3A4 P08684 2/20 0.66
NFKB1 P19838 2/20 0.66
TSHR P16473 2/20 0.66
CYP2C9 P11712 1/20 0.66
KCNK3 O14649 1/20 0.66
CACNA1F O60840 1/20 0.66
KCNK2 O95069 1/20 0.66
GBA1 P04062 1/20 0.66
MAOA P21397 1/20 0.66
HTR2A P28223 1/20 0.66
SLC6A4 P31645 1/20 0.66
HTR2B P41595 1/20 0.66
SCN7A Q01118 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7701472 1.00 SCN4A (0.66) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL7701144 1.00 SCN4A (0.66) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL11329870 0.87 SCN4A (0.51) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL10636052 0.87 SCN4A (0.56) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL5607510 0.85 TSHR (0.73) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL15241352 0.83 SCN4A (0.78) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL8238232 0.83 SCN4A (0.70) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL14509238 0.82 SCN5A (0.54) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL23598063 0.80 TSHR (0.67) SCN4ALMNACYP2D6SCN1ASCN5A
SCHEMBL11464779 0.80 TSHR (0.67) SCN4ALMNACYP2D6SCN1ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3200749-A None JP disclosed
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2019-09-05 US disclosed
CN-102603543-B Preparation method of mexiletine hydrochloride FOSHAN PRIZEN MEDICAL TECHNOLOGY CO LTD 2014-07-02 CN disclosed
CN-101529011-B Method for the treatment of substrates BASF SE 2012-12-12 CN disclosed
CN-102603543-A Preparation method of mexiletine hydrochloride FOSHAN PRIZEN MEDICAL TECHNOLOGY CO LTD 2012-07-25 CN disclosed
CN-101529011-A Method for the treatment of substrates BASF SE (DE) 2009-09-09 CN disclosed
EP-1037871-B1 NOVEL ANTIARRHYTHMIC COMPOUNDS GYOGYSZERKUTATO INTEZET (HU) 2002-07-03 EP disclosed
US-6265445-B1 CARDIOVASCULAR DISORDERS GYOGYSZERKUTATO INTEZET KFT (HU) 2001-07-24 US disclosed
EP-1037871-A1 NOVEL ANTIARRHYTHMIC COMPOUNDS GYOGYSZERKUTATO INTEZET KFT. (HU) 2000-09-27 EP disclosed
WO-1999029655-A1 NOVEL ANTIARRHYTHMIC COMPOUNDS Gyógyszerkutató Intézet Kft. (HU) 1999-06-17 WO disclosed
US-5420352-A Reaction of alcohol with ammonia to form amine in a solvent in the presence of copper chromium catalyst and hydrogen IDEMITSU KOSAN CO., LTD. (JP) 1995-05-30 US disclosed
EP-0492615-B1 Process for producing biguanide derivative IDEMITSU KOSAN CO (JP) 1995-03-08 EP disclosed
EP-0619294-A1 PROCESS FOR PRODUCING 1-PHENOXY-2-AMINOPROPANE IDEMITSU KOSAN COMPANY LIMITED (JP) 1994-10-12 EP disclosed
US-5286905-A Heating hydrogen halide salt of phenoxyalkylamine with dicyandiamide in paraffinic hydrocarbon solvent IDEMITSU KOSAN COMPANY LIMITED (JP) 1994-02-15 US disclosed
EP-0492615-A1 Process for producing biguanide derivative IDEMITSU KOSAN COMPANY LIMITED (JP) 1992-07-01 EP disclosed
JP-H03200749-A PRODUCTION OF PHENOXYPROPYLAMINE MITSUI TOATSU CHEM INC 1991-09-02 JP disclosed
US-4082808-A ANTIOXIDANTS, INTERMEDIATES FOR POLYESTERS, POLYCARBONATES, EPOXY RESINS GENERAL ELECTRIC COMPANY (US) 1978-04-04 US disclosed
US-4064158-A Process for the preparation of an organomercaptophenol from sulfur, a 2,6-disubstituted phenol, and an activated olefin or an epoxy compound GENERAL ELECTRIC COMPANY (US) 1977-12-20 US disclosed
US-3979460-A ANTIOXIDANTS GENERAL ELECTRIC COMPANY (US) 1976-09-07 US disclosed
US-3953519-A BASES, EPOXY COMPOUNDS, OLEFINS GENERAL ELECTRIC COMPANY (US) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS SCN1B, CACNA1E, SCN2B SCN4A 48/4885LMNA 1789/4885CYP2D6 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.